Neoadjuvant Semaglutide, Bariatric Surgery Weight Loss, and Overall Outcomes
JAMA Surgery · 01.05.2025 · 160 (5) · 594
DOI: 10.1001/jamasurg.2025.0001 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Surgery, erschienen am 01.05.2025. Verfasst von Vasundhara Mathur und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Surgical and Metabolic Research, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
This case-control study examines the use of glucagon-like peptide-1 receptor agonist before metabolic and bariatric surgery and its postoperative outcome.
Autor:innen und Institutionen
- Laboratory for Surgical and Metabolic Research, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Zitieren
APA
Mathur, V., Wasden, K., Shin, T. H., Medhati, P., Nimeri, A. A., Tavakkoli, A., & Sheu, E. G. (2025). Neoadjuvant Semaglutide, Bariatric Surgery Weight Loss, and Overall Outcomes. JAMA Surgery, 160(5), 594. https://doi.org/10.1001/jamasurg.2025.0001
Vancouver
Mathur V, Wasden K, Shin TH, Medhati P, Nimeri AA, Tavakkoli A, et al. Neoadjuvant Semaglutide, Bariatric Surgery Weight Loss, and Overall Outcomes. JAMA Surgery. 2025;160(5):594. doi:10.1001/jamasurg.2025.0001
BibTeX
@article{Mathur2025,
author = {Mathur, Vasundhara and Wasden, Katherine and Shin, Thomas H and Medhati, Pourya and Nimeri, Abdelrahman A and Tavakkoli, Ali and Sheu, Eric G},
title = {Neoadjuvant Semaglutide, Bariatric Surgery Weight Loss, and Overall Outcomes},
journal = {JAMA Surgery},
year = {2025},
volume = {160},
number = {5},
pages = {594},
doi = {10.1001/jamasurg.2025.0001}
}
EUVIMED